Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 01 October 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Fructose and lactose intolerance and malabsorption testing

A study published ahead of print in the Alimentary Pharmacology & Therapeutics examines the relationship between fructose and lactose intolerance with symptoms in functional gastrointestinal disorders

News image

The association of fructose and lactose intolerance and malabsorption with the symptoms of different functional gastrointestinal disorders remains unclear.

Professor Wilder-Smith and colleagues from Switzerland investigated the prevalence of fructose and lactose intolerance and malabsorption, and their association with clinical gastrointestinal as well as non-clinical gastrointestinal symptoms in functional gastrointestinal.

In addition, the team examined the outcome of dietary intervention.

The research team demonstrated fructose and lactose intolerance and malabsorption in 1372 functional gastrointestinal disorders patients in a single center using breath testing.

Results were correlated with clinical symptoms in different functional gastrointestinal disorders Rome III subgroups.

The doctors assessed that the effectiveness of a targeted saccharide-reduced diet after 6–8 weeks.

Intolerance prevalence across all functional gastrointestinal disorders was 60% to fructose, 51% to lactose, and 33% to both.

Malabsorption occurred in 45%, 32% and 16% respectively.

Adequate symptom relief was achieved in 80% of intolerant patients
Alimentary Pharmacology & Therapeutics

The research team found that there were no differences in intolerance or malabsorption prevalence between functional gastrointestinal disorders subgroups.

Functional gastrointestinal disorders symptoms correlated with symptoms evoked during testing, but not with malabsorption.

The team of doctors found that non-clinical gastrointestinal symptoms occurred more commonly in patients with intolerances.

Methane breath levels were not associated with constipation using several cut-off thresholds.

The research team noted that adequate symptom relief was achieved in 80% of intolerant patients, irrespective of malabsorption.

Fructose and lactose intolerances are common in functional gastrointestinal disorders and associated with increased non-clinical gastrointestinal symptoms, but not with specific functional gastrointestinal disorders subtypes.

Professor Wilder-Smith's team concluded, "Symptoms experienced during breath testing, but not malabsorption, correlate with functional gastrointestinal disorders symptoms.

"Effective symptom relief with dietary adaptation is not associated with malabsorption."

"Mechanisms relating to the generation of clinical gastrointestinal and non-clinical gastrointestinal symptoms due to lactose and fructose in functional gastrointestinal disorders need to be explored further."

Aliment Pharmacol Ther 2013: DOI: 10.1111/apt.12306
12 April 2013

Go to top of page Email this page Email this page to a colleague

 30 September 2016 
Gluten breakdown and immunogenicity in celiac disease
 30 September 2016 
Noninvasive detection of NASH
 30 September 2016 
CEA levels to detect recurrent colorectal cancer
 29 September 2016 
Biologic therapies in IBD
 29 September 2016 
Predicting the prognosis of gastric cancer
 29 September 2016 
Predicting symptomatic outcomes in GERD
 28 September 2016 
Hep C virus RNA in liver explants
 28 September 2016 
Global trends in pancreatic cancer mortality
 28 September 2016 
Heterogeneity in endoscopic treatment of Crohn’s
 27 September 2016 
Non-invasive tests of NAFLD
 27 September 2016 
Fecal microbiota transplantation for C.diff in IBD
 27 September 2016 
Fast-track colorectal surgery influences outcomes
 26 September 2016 
Preventing cirrhosis in Hep C with fibrosis
 26 September 2016 
Body image after abdominoperineal excision for rectal cancer
 26 September 2016 
Gastric cancer risk in intestinal metaplasia of the stomach
 23 September 2016 
Sleep quality in nonalcoholic cirrhotic patients
 23 September 2016 
Exercise for NAFLD
 23 September 2016 
BMI history and fatty liver
 22 September 2016 
Predicting small-bowel Crohn’s disease
 22 September 2016 
Colectomy outcomes for ulcerative colitis
 22 September 2016 
Technology vs intervention for weight loss
 21 September 2016 
Employment status and IBD
 21 September 2016 
Cardiopulmonary exercise testing in liver transplant candidates
 21 September 2016 
Patients vs providers on nutrition in IBD
 20 September 2016 
Improving healthcare systems for viral Hepatitis
 20 September 2016 
GI benefits of COX-2 selective inhibitors
 20 September 2016 
Predicting relapse in Crohn's
 19 September 2016 
Prevalence of esophageal cancer in Barrett's
 19 September 2016 
Fecal microbiota transplantation and CDI in IBD
 19 September 2016 
Antibiotic resistance in Helicobacter pylori
 16 September 2016 
Low-residue diet before colonoscopy and bowel cleansing
 16 September 2016 
Genome-wide association in gastric cancer
 16 September 2016 
H. pylori in children with asthma
 15 September 2016 
Improving survival in cholangitis-associated septic shock
 15 September 2016 
Colorectal cancer survival and hospital volumes
 15 September 2016 
Primary sclerosing cholangitis and IBD
 14 September 2016 
Intestinal malabsorption and olmesartan
 14 September 2016 
Infection reduction strategy after colorectal resection
 14 September 2016 
Predicting long-term infliximab use in Crohn's
 13 September 2016 
Predicting survival in refractory celiac disease
 13 September 2016 
Cancer risk stratification in Barrett’s
 13 September 2016 
Screening vs non-screening colonoscopy
 12 September 2016 
Screening in familial colorectal cancer
 12 September 2016 
Metformin improves survival in pancreatic ductal cancer
 12 September 2016 
Consent guidelines for GI endoscopy procedures
 09 September 2016 
Development of IBS
 09 September 2016 
Safe and effective treatment for NASH
 09 September 2016 
Scale for stool measurement in diarrhea-IBS
 08 September 2016 
Prognostic factors for infliximab in Crohn's
 08 September 2016 
Chronic Hep B vs chronic Hep C and mortality
 08 September 2016 
Hematological malignancies in IBD
 07 September 2016 
IBD relapse during pregnancy
 07 September 2016 
New treatments for ulcerative colitis
 07 September 2016 
Alternative to nucleic acid testing in HCV
 06 September 2016 
EHealth technologies in IBD
 06 September 2016 
Endoscopy clinic no-shows
 06 September 2016 
Risk of infection after elective colorectal surgery
 05 September 2016 
Esophageal impedance monitoring
 05 September 2016 
Family history and IBD clinical course
 05 September 2016 
Biomarker for IBD and GI cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us